Regenix Drugs has commissioned Tamil Nadu's first biosimilar insulin manufacturing facility, making it only the fifth in India. 

The new plant in Tambaram will produce Sustaglar, a long-acting glargine insulin aimed at making diabetes treatment more affordable and accessible. 

The facility, built with an investment of Rs 50 crore over five years, has an initial capacity of 200 litres, which can be expanded to 1,000 litres.

Sustaglar is designed to provide stable 24-hour blood sugar control with less hypoglycemia. 

Regenix is also launching India's first disposable insulin pen, priced at half the cost of reusable pens, along with smaller 3 ml vials to further reduce expenses for patients. 

With the basal insulin market in India valued at Rs 2,000 crore, Regenix is targeting a 10% share while simultaneously pursuing approvals for overseas markets.